In the opening CME session at EAS 2022 chaired by Lale Tokgözoğlu, Turkey and Kausik K. Ray, United Kingdom, experts discussed the role of incretin therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in atherosclerosis and their potential in preventing adverse cardiovascular outcomes in an era where the prevalence of obesity and...
EAS 2022 — Are incretins the key to CVD prevention in the era of obesity and diabetes?
Pavankumar Kamat | Conference Report | 26 May 2022
Register or log in to read more
Registration is free and easy, giving you complete access to all Univadis content.Create a Free Account I have an account